Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Nucleoside Analogs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113881728B reveals a chemo-enzymatic route for PreQ 1, enhancing yield and reducing waste for pharmaceutical intermediate manufacturing supply chains.
Patent CN107108681B reveals a high-purity nucleoside analog synthesis route eliminating chromatography, offering significant cost and supply chain advantages for pharmaceutical manufacturers.
Patent CN110642843A details a novel Pd-catalyzed asymmetric [3+2] cyclization for chiral isonucleosides, offering high enantioselectivity and streamlined supply chains for API manufacturing.
Patent CN110642843A reveals a novel Pd-catalyzed asymmetric [3+2] cyclization for high-purity chiral isonucleosides, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN112638925B reveals stable 3'-OH blocking groups for SBS. Enhances sequencing read lengths and reduces cost reduction in sequencing reagent manufacturing.
Patent CN105732631A reveals efficient N9 vinyl purine synthesis. Offers cost reduction in pharmaceutical intermediates manufacturing with high yield and scalability.
Patent CN107501267B reveals Pd-catalyzed asymmetric allylic amination for high-purity nucleoside intermediates. Enables cost reduction and supply chain reliability.
Patent CN108314655A enables high-purity chiral nucleoside synthesis with 99% ee, reducing API manufacturing costs and ensuring reliable supply chain for pharmaceutical intermediates.